Conception and reality: Outcome of SARS-CoV-2 infection and vaccination among Hungarian IBD patients on biologic treatments
Introduction: Inflammatory bowel disease potentially elevates the risk of infections, independently from age, while the disease activity and medical treatment(s) can also increase the risks. Nevertheless, it is necessary to clarify these preconceptions as well during the COVID-19 pandemic. Methods:...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-04-01
|
| Series: | Vaccine: X |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590136222001139 |
| _version_ | 1797853942669901824 |
|---|---|
| author | Tamás Resál Mária Matuz Csilla Keresztes Péter Bacsur Kata Szántó Anett Sánta Mariann Rutka Diána Kolarovszki-Erdei Renata Bor Anna Fábián Zoltán Szepes Pál Miheller Patrícia Sarlós Anita Zacháry Klaudia Farkas Tamás Molnár |
| author_facet | Tamás Resál Mária Matuz Csilla Keresztes Péter Bacsur Kata Szántó Anett Sánta Mariann Rutka Diána Kolarovszki-Erdei Renata Bor Anna Fábián Zoltán Szepes Pál Miheller Patrícia Sarlós Anita Zacháry Klaudia Farkas Tamás Molnár |
| author_sort | Tamás Resál |
| collection | DOAJ |
| description | Introduction: Inflammatory bowel disease potentially elevates the risk of infections, independently from age, while the disease activity and medical treatment(s) can also increase the risks. Nevertheless, it is necessary to clarify these preconceptions as well during the COVID-19 pandemic. Methods: An observational, questionnaire based study was conducted in Hungary between February and August 2021. 2 questionnaires were completed. The first questionnaire surveyed the impact of the pandemic on patients with biologic treatments and assessed the severity and outcome of the infection, whereas the second one assessed vaccination rate and adverse events. Results: 472 patients participated in the study. 16.9 % of them acquired the infection and 6.3 % needed hospitalization. None of them required ICU care. Male sex elevated the risk of infection (p = 0.008), while glove (p = 0.02) and mask wearing (p = 0.005) was the most effective prevention strategy. Nevertheless, abstaining from community visits or workplace did not have an impact on the infection rate. Smoking, age, and disease type did not elevate the risk. UC patients had poorer condition during the infection (p = 0.003); furthermore, the disease activity could potentially worsen the course of infection (p = 0.072). The different biological treatments were equally safe; no difference was observed in the infection rate, course of COVID-19. Azathioprine and corticosteroids did not elevate the infection rate. 28 patients (35.0 %) suspended the ongoing biologic treatment, but it had no impact on the disease course. However, it resulted in changing the current treatment (p = 0.004). 9.8 % of the respondents were sceptic about being vaccinated, and 90 % got vaccinated. In one case, a serious flare-up occurred. Discussion: Most patients acquired the infection at workplace. Biologic therapies had no effect on the COVID-19 infection, whereas male sex, an active disease, and UC could be larger threat than treatments. Vaccination was proved to be safe, and patient education is important to achieve mass vaccination of the population. |
| first_indexed | 2024-04-09T19:57:53Z |
| format | Article |
| id | doaj.art-bef18fcb500f4bc6946cfb7636ac1936 |
| institution | Directory Open Access Journal |
| issn | 2590-1362 |
| language | English |
| last_indexed | 2024-04-09T19:57:53Z |
| publishDate | 2023-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Vaccine: X |
| spelling | doaj.art-bef18fcb500f4bc6946cfb7636ac19362023-04-03T05:22:46ZengElsevierVaccine: X2590-13622023-04-0113100253Conception and reality: Outcome of SARS-CoV-2 infection and vaccination among Hungarian IBD patients on biologic treatmentsTamás Resál0Mária Matuz1Csilla Keresztes2Péter Bacsur3Kata Szántó4Anett Sánta5Mariann Rutka6Diána Kolarovszki-Erdei7Renata Bor8Anna Fábián9Zoltán Szepes10Pál Miheller11Patrícia Sarlós12Anita Zacháry13Klaudia Farkas14Tamás Molnár15Gastroenterology Unit, Department of Medicine, University of Szeged, Szeged, HungaryDepartment of Clinical Pharmacy, University of Szeged, Szeged, HungaryDepartment for Medical Communication and Translation Studies, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, HungaryGastroenterology Unit, Department of Medicine, University of Szeged, Szeged, HungaryGastroenterology Unit, Department of Medicine, University of Szeged, Szeged, HungaryGastroenterology Unit, Department of Medicine, University of Szeged, Szeged, HungaryGastroenterology Unit, Department of Medicine, University of Szeged, Szeged, HungaryGastroenterology Unit, Department of Medicine, University of Szeged, Szeged, HungaryGastroenterology Unit, Department of Medicine, University of Szeged, Szeged, HungaryGastroenterology Unit, Department of Medicine, University of Szeged, Szeged, HungaryGastroenterology Unit, Department of Medicine, University of Szeged, Szeged, HungaryDepartment of Surgery and Interventional Gastroenterology, Semmelweis University, Budapest, HungaryGastroenterology Unit, 1st Department of Medicine, University of Pécs, Pécs, HungaryHungarian Crohn's and Colitis Association, Budapest, HungaryGastroenterology Unit, Department of Medicine, University of Szeged, Szeged, HungaryGastroenterology Unit, Department of Medicine, University of Szeged, Szeged, Hungary; Corresponding author.Introduction: Inflammatory bowel disease potentially elevates the risk of infections, independently from age, while the disease activity and medical treatment(s) can also increase the risks. Nevertheless, it is necessary to clarify these preconceptions as well during the COVID-19 pandemic. Methods: An observational, questionnaire based study was conducted in Hungary between February and August 2021. 2 questionnaires were completed. The first questionnaire surveyed the impact of the pandemic on patients with biologic treatments and assessed the severity and outcome of the infection, whereas the second one assessed vaccination rate and adverse events. Results: 472 patients participated in the study. 16.9 % of them acquired the infection and 6.3 % needed hospitalization. None of them required ICU care. Male sex elevated the risk of infection (p = 0.008), while glove (p = 0.02) and mask wearing (p = 0.005) was the most effective prevention strategy. Nevertheless, abstaining from community visits or workplace did not have an impact on the infection rate. Smoking, age, and disease type did not elevate the risk. UC patients had poorer condition during the infection (p = 0.003); furthermore, the disease activity could potentially worsen the course of infection (p = 0.072). The different biological treatments were equally safe; no difference was observed in the infection rate, course of COVID-19. Azathioprine and corticosteroids did not elevate the infection rate. 28 patients (35.0 %) suspended the ongoing biologic treatment, but it had no impact on the disease course. However, it resulted in changing the current treatment (p = 0.004). 9.8 % of the respondents were sceptic about being vaccinated, and 90 % got vaccinated. In one case, a serious flare-up occurred. Discussion: Most patients acquired the infection at workplace. Biologic therapies had no effect on the COVID-19 infection, whereas male sex, an active disease, and UC could be larger threat than treatments. Vaccination was proved to be safe, and patient education is important to achieve mass vaccination of the population.http://www.sciencedirect.com/science/article/pii/S2590136222001139SARS-CoV-2Inflammatory bowel diseasePandemicBiologic treatment |
| spellingShingle | Tamás Resál Mária Matuz Csilla Keresztes Péter Bacsur Kata Szántó Anett Sánta Mariann Rutka Diána Kolarovszki-Erdei Renata Bor Anna Fábián Zoltán Szepes Pál Miheller Patrícia Sarlós Anita Zacháry Klaudia Farkas Tamás Molnár Conception and reality: Outcome of SARS-CoV-2 infection and vaccination among Hungarian IBD patients on biologic treatments Vaccine: X SARS-CoV-2 Inflammatory bowel disease Pandemic Biologic treatment |
| title | Conception and reality: Outcome of SARS-CoV-2 infection and vaccination among Hungarian IBD patients on biologic treatments |
| title_full | Conception and reality: Outcome of SARS-CoV-2 infection and vaccination among Hungarian IBD patients on biologic treatments |
| title_fullStr | Conception and reality: Outcome of SARS-CoV-2 infection and vaccination among Hungarian IBD patients on biologic treatments |
| title_full_unstemmed | Conception and reality: Outcome of SARS-CoV-2 infection and vaccination among Hungarian IBD patients on biologic treatments |
| title_short | Conception and reality: Outcome of SARS-CoV-2 infection and vaccination among Hungarian IBD patients on biologic treatments |
| title_sort | conception and reality outcome of sars cov 2 infection and vaccination among hungarian ibd patients on biologic treatments |
| topic | SARS-CoV-2 Inflammatory bowel disease Pandemic Biologic treatment |
| url | http://www.sciencedirect.com/science/article/pii/S2590136222001139 |
| work_keys_str_mv | AT tamasresal conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments AT mariamatuz conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments AT csillakeresztes conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments AT peterbacsur conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments AT kataszanto conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments AT anettsanta conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments AT mariannrutka conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments AT dianakolarovszkierdei conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments AT renatabor conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments AT annafabian conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments AT zoltanszepes conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments AT palmiheller conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments AT patriciasarlos conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments AT anitazachary conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments AT klaudiafarkas conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments AT tamasmolnar conceptionandrealityoutcomeofsarscov2infectionandvaccinationamonghungarianibdpatientsonbiologictreatments |